| Trial ID: | L3681 |
| Source ID: | NCT00621868
|
| Associated Drug: |
Ipragliflozin
|
| Title: |
A Study of ASP1941 in Participants With Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus
|
| Interventions: |
DRUG: ipragliflozin|DRUG: Placebo
|
| Outcome Measures: |
Primary: HbA1c level, 12 weeks | Secondary: Blood glucose level, 12 Weeks|Safety, 12 Weeks
|
| Sponsor/Collaborators: |
Sponsor: Astellas Pharma Inc
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
361
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2008-03-26
|
| Completion Date: |
2009-03-14
|
| Results First Posted: |
|
| Last Update Posted: |
2024-11-12
|
| Locations: |
Chubu, Japan|Chugoku, Japan|Hokkaidou, Japan|Kansai, Japan|Kantou, Japan|Kyushu, Japan|Shikoku, Japan|Touhoku, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT00621868
|
